Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C

References

• Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67
   PubMed Web of Science ®Google Scholar
• Bernstein D, Kleinman L, Barker CM, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-8
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004;40:675-81
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Ware JE Jr, Bayliss MS, et al. Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-7
   PubMed Web of Science ®Google Scholar
• Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A] in patients with chronic hepatitis C. Pharmacoeconomics 2003;21:341-9
   PubMed Web of Science ®Google Scholar
• Hepatitis C. WHO Web site. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html. Published 2002. Accessed December 30, 2008
   Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-81
   PubMed Web of Science ®Google Scholar
• Bacon B, Regev A, Ghalib RH, et al. The DIRECT trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy). Treatment of non-responders to previous pegylated interferon plus ribavirin: sustained virologic response data. Presented at: 58th Annual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007, Boston, MA, USA. Abstr 168
   Google Scholar
• Marcellin P, Freilich B, Andreone P, et al. HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2b/RBV: results from REPEAT study. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008Milan, Italy. Abstr 805
   Google Scholar
• Poynard T, Schiff E, Terg R, et al. SVR is dependent on baseline characteristics in the retreatment of previous alfa-IFN/RBV NRs: final results from the EPIC3 program. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy. Abstr 988
   Google Scholar
• Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9
   PubMed Web of Science ®Google Scholar
• Subramanian GM, Fiscella M, Lamousé-Smith A, et al. Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nature Biotech 2007;25:1411-19
   PubMed Web of Science ®Google Scholar
• Osborn BL, Sekut L, Corcoran M, et al. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol 2002;456:149-58
   PubMed Web of Science ®Google Scholar
• Halpern W, Riccobene TA, Agostini H, et al. Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res 2002;19:1720-9
   PubMed Web of Science ®Google Scholar
• Melder RJ, Osborn BL, Riccobene T, et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother 2005;54:535-47
   PubMed Web of Science ®Google Scholar
• Baggio LL, Huang Q, Brown TJ, et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53:2492-500
   PubMed Web of Science ®Google Scholar
• Wang W, Ou Y, Shi Y. AlbuBNP, a recominant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004;21:2105-11
   PubMed Web of Science ®Google Scholar
• Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem 1994;45:153-203
   PubMedGoogle Scholar
• Zunszain PA, Ghuman J, Komatsu T, et al. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol 2003;3:6
   PubMedGoogle Scholar
• Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303:540-8
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu H, Subramanian GM, et al. Anti-HCV activity of albinterferon alfa-2b in cell culture. Hepatol Res 2007;37:941-7
   PubMed Web of Science ®Google Scholar
• Balan V. Albumin-interferon-α in the treatment of chronic hepatitis C. Fut Virol 2006;1:269-77
   Web of Science ®Google Scholar
• Balan V, Nelson D, Sulkowski M, et al. Molecular profiles of drug response in HCV infected patients during the first 4 weeks of therapy for chronic hepatitis C virus with pegylated interferon containing regimens or albuferon. Hepatology 2003;38 (Suppl 1):630A Abstr 984
   Web of Science ®Google Scholar
• Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006;44:671-8
   PubMed Web of Science ®Google Scholar
• Balan V, Nelson DR, Sulkowski MS, et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006;11:35-45
   PubMed Web of Science ®Google Scholar
• Balan V, Nelson DR, Sulkowski MS, et al. Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. Antivir Ther 2006;11:901-8
   PubMed Web of Science ®Google Scholar
• Fiscella M, Balan V, Nelson D, et al. Favorable pharmacokinetics of albumin interferon alfa-2b in subjects with chronic hepatitis C. Hepatology 2006;44 (Suppl 1):613A Abstr 1140
   Web of Science ®Google Scholar
• Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. Hepatology 2005;42:749-54
   PubMed Web of Science ®Google Scholar
• Neumann AU, Rozenberg L, Bain VG, et al. Viral kinetics and pharmacodynamics of albinterferon alfa-2b in interferon treatment-naïve patients with genotype 1, chronic hepatitis C. J Hepatol 2008;48:306 Abstr 818
   Web of Science ®Google Scholar
• Bain VG, Kaita KD, Marotta P, et al. Safety and antiviral activity of albinterferon alfa-2b dosed every 4 weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:701-6
   PubMed Web of Science ®Google Scholar
• Nelson DR, Rustgi V, Balan V, et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 2009;7:212--8.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every 2 or 4 weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008;48:407-17
   PubMed Web of Science ®Google Scholar
• Forestier N, Reesink HW, Wegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-8
   PubMed Web of Science ®Google Scholar